Dimensional Fund Advisors LP raised its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 968.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 107,580 shares of the company’s stock after acquiring an additional 97,510 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.17% of Viridian Therapeutics worth $1,400,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently modified their holdings of the company. Ameritas Investment Partners Inc. lifted its position in Viridian Therapeutics by 19.2% during the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after purchasing an additional 799 shares in the last quarter. Quest Partners LLC grew its stake in shares of Viridian Therapeutics by 344.0% during the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock valued at $79,000 after acquiring an additional 4,692 shares during the period. Principal Financial Group Inc. increased its holdings in Viridian Therapeutics by 9.7% in the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after acquiring an additional 1,058 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Viridian Therapeutics by 24.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock worth $156,000 after acquiring an additional 2,359 shares during the period. Finally, AlphaCentric Advisors LLC lifted its holdings in Viridian Therapeutics by 108.3% during the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock valued at $163,000 after purchasing an additional 6,500 shares in the last quarter.
Insider Buying and Selling at Viridian Therapeutics
In related news, COO Thomas W. Beetham bought 5,000 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was purchased at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the acquisition, the chief operating officer now owns 6,000 shares in the company, valued at $140,460. This trade represents a 500.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, COO Thomas W. Beetham bought 5,000 shares of the stock in a transaction dated Friday, September 27th. The stock was purchased at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the acquisition, the chief operating officer now owns 6,000 shares of the company’s stock, valued at $140,460. The trade was a 500.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Stephen F. Mahoney purchased 21,400 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the acquisition, the chief executive officer now directly owns 21,400 shares in the company, valued at $499,262. The disclosure for this purchase can be found here. Insiders have purchased a total of 1,626,400 shares of company stock worth $30,616,312 over the last ninety days. Company insiders own 0.65% of the company’s stock.
Viridian Therapeutics Price Performance
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.15). The business had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. Sell-side analysts forecast that Viridian Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on VRDN. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, September 10th. Royal Bank of Canada reissued an “outperform” rating and set a $44.00 price target on shares of Viridian Therapeutics in a report on Thursday, September 19th. Oppenheimer reaffirmed an “outperform” rating and issued a $28.00 price objective (down previously from $31.00) on shares of Viridian Therapeutics in a research note on Monday, August 12th. BTIG Research lifted their target price on Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday, September 26th. Finally, The Goldman Sachs Group upped their price target on Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $35.80.
View Our Latest Stock Analysis on Viridian Therapeutics
Viridian Therapeutics Company Profile
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Featured Articles
- Five stocks we like better than Viridian Therapeutics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Health Care Stocks Explained: Why You Might Want to Invest
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.